vendredi 16 novembre 2018

Onco Actu du 16 novembre 2018

1. Biologie

By solving a mystery of gene repair, scientists uncover an exception to biology’s rules [UNC]

2.6 Etiologie - Environnement

California judge orders next Monsanto weed-killer cancer trial for March [Reuters]

3.1.1 Prévention - Tabac - e-cigs

Stanford tobacco researcher weighs in on JUUL [Stanford Medicine]

Statement from FDA Commissioner Scott Gottlieb, M.D., on proposed new steps to protect youth by preventing access to flavored tobacco products and banning menthol in cigarettes [FDA]

Results from 2018 National Youth Tobacco Survey show dramatic increase in e-cigarette use among youth over past year [FDA]

Juul Can Breathe After Dodging Full FDA Ban on Flavored E-Cigs [Wired]

Q&A: The ABCs of E-Cigarettes [NY Times]

3.4 Chimioprévention

How some journalists got hooked by fish oil and vitamin D spin [HealthNewsReview]

4. Dépistage, diagnostic et pronostic

Outsourcing firms could be banned from carrying out NHS cancer screening services [The Telegraph]

4.12 Biopsies liquides

A new approach to detecting cancer earlier from blood tests: study [UHN Toronto]

4.2 Dép., diag. & prono. - Génome

Offering free DNA sequencing, Nebula Genomics opens for business. But there’s an itsy-bitsy catch [STAT]

Startup Offers To Sequence Your Genome Free Of Charge, Then Let You Profit From It [NPR]

Nebula Genomics Touts Free DNA Sequencing to Coax Health Data Sharing [Xconomy]

5.10 Traitements - Essais

NCI-MATCH Update: More Labs, New Arms, and Initial Findings [NCI]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

The sandbox: Parker Institute throws its research muscle behind gene therapy tech for destroying cancer cells [EndPoints]

5.12.4 Immunothérapies - Essais

AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer [AstraZeneca]

AstraZeneca's key lung cancer treatment fails main goal in late-stage trial [Reuters]

5.12.6 Immunothérapies - AMM

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma [BMS]

5.12.8 Immunothérapies - Economie

NICE recommends cutting-edge therapy for young people with blood cancer [NICE]

5.2 Pharma

FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas [Seattle Genetics]

5.2.1 Pharma - Partenariats

Boehringer Ingelheim and Epizyme launch $300M precision oncology program [FierceBiotech]

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies [Boehringer Ingelheim]

5.4 Traitements - Economie

Final NICE green light for Pfizer’s Mylotarg [PharmaTimes]

5.9.4 ENA

Patients with rare, incurable digestive tract cancers respond to new drug combination [ECCO]

6.10 Politiques

China’s crackdown on genetics breaches could deter data sharing [Nature]

6.9 Controverses

Johnson & Johnson scores back-to-back victories in talc mesothelioma cases [FiercePharma]